Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves’ Hyperthyroidism: The RISG Study
Table 1
Baseline characteristics of the included patients. Remission was prespecified and defined as TRAb < 1.0 IU/L and TSH ≥ 0.40 mU/L in a patient on a MMI dose of 5 mg or less per day on two blood samples taken two months apart.
Remission
No remission
All
P (remission vs no
Participant, n (%)
92 (53.8)
81 (46.2)
173 (100)
-
Sex, M/F (%F)
13/79 (85.9)
10/71 (87.7)
23/150 (86.7)
0.824
Age, years, median (IQR)
43 (34 – 51)
48 (39 – 55)
44 (36.0 – 52.5)
0.024
History of hyperthyroidism, n (%)
4 (4.3)
5 (6.3)
9 (5.2)
0.736
Smoker, n (%)
26 (28.0)
22 (27.5)
48 (27.7)
0.867
Estrogen use, n (%)
15 (16.1)
14 (17.5)
29 (16.8)
1.00
GD in 1st generation relatives, n (%)
22 (23.7)
22 (27.5)
44 (25.4)
0.381
BMI kg/m2, median (IQR)
23.5 (21.1 – 27.1)
22.5 (20.1 – 25.6)
23.0 (20.7 – 26.1)
0.034
None or minor eye symptoms, n (%)
73 (78.5)
53 (62.5)
127 (73.4)
0.172
Thyroid volume ml, median (IQR)
19.7 (13.2 – 26.7)
20.5 (15.0 – 35.8)
20.0 (14.6 – 30.9)
0.187
S-T4 nmol/L, median (IQR)
203 (165 – 250)
227 (187 – 285)
211 (175 – 263)
0.010
S-T3 nmol/L, median (IQR)
5.4 (4.0 – 6.8)
5.5 (4.6 – 8.2)
5.4 (4.1 – 7.2)
0.139
S-TRAb IU/L, median (IQR)
7.00 (3.80 – 11.1)
11.5 (7.73 – 22.0)
8.9 (5.1 – 15.6)
<0.001
S-TPO kU/L, median (IQR)
206 (30 – 1791)
459 (30 – 3600)
268 (30 – 2645)
0.443
s-TG ab
35 (16 – 104)
25 (10 – 147)
28.5 (14 – 110)
0.406
u-iodine, µg/L, median (IQR)
132 (80- 208.5)
159 (98.3 – 284.8)
141 (86 – 264)
0.144
-Whitney or Chi square/Fisher exact test as appropriate. n = number. M = male. F = female. IQR = interquartile range.
